Aurinia Pharmaceuticals Inc (AUPH) Dividend History

Aurinia Pharmaceuticals Inc. is a global biotechnology company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. The company's flagship product, Lupkynis, is approved for the treatment of lupus nephritis, a serious complication of systemic lupus erythematosus. Aurinia specializes in innovative treatments targeting immune system pathways to address unmet medical needs.

#140, 14315 - 118 Avenue, Edmonton, A0, T5L 4S6
Phone: 250-744-2487
Website: https://www.auriniapharma.com

Dividend History

Aurinia Pharmaceuticals Inc currently does not pay dividends

Company News

New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights

The American College of Rheumatology has updated its guidelines for treating lupus nephritis, recommending early use of triple therapy (mycophenolate mofetil, glucocorticoids, and either Benlysta or a calcineurin inhibitor). However, current practice often delays initiating triple therapy until initial treatment failure.

GlobeNewswire Inc.
Corporate and Individual Donations Provide Much-Needed Support to Kidney Patients Impacted by Hurricane Helene Through the American Kidney Fund’s Disaster Relief Program

The American Kidney Fund's Disaster Relief Program is providing emergency financial assistance to dialysis and recent transplant patients in areas affected by Hurricane Helene. The program has received generous support from various companies and individual donors to help cover expenses related to lost medications, housing, transportation, and personal essentials.

GlobeNewswire Inc.

Featured Companies: ARDX
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research

Featured Companies: ESPR
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%

The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 82.35% and 8.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Featured Companies: CPRX

Dividend data last updated 06/07/2025 05:09:44 UTC